Hillman, Patti, Weinreb receive ACR Gold Medal

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American College of Radiology board of selected three innovators as 2017 Gold Medalists for their extraordinary service to the college or radiology. Honors will be presented bestowed during ACR 2017 – The Crossroads of Radiology meeting in Washington May 21-25, 2017.

The following individuals will receive the ACR Gold Medal:

  • Bruce Hillman, of Wake Forest, NC, professor of radiology and medical imaging and health evaluation sciences and former chair of radiology, University of Virginia, and founding and current editor-in-chief of the Journal of the American College of Radiology,

  • John Patti, of Lynnfield, MA, senior lecturer in radiology at Harvard Medical School and thoracic radiologist at Massachusetts General Hospital and Harvard Medical School, and past chair of the board and president of ACR,

  • Jeffrey C. Weinreb, of New Haven, CT, professor of radiology and biomedical imaging and vice chair for strategic planning and innovation at Yale-New Haven Hospital/Yale School of Medicine, and past BOC member and vice-president of ACR

The following candidates were approved to receive Honorary Fellowships in recognition of their contributions to the science or practice of radiology:

  • Berend J. Slotman, of Amsterdam, professor and chair of radiation oncology, VU University Medical Center Amsterdam,
  • Jacob Sosna, of Jerusalem, chair, division of imaging, Hadassah Hebrew University Medical Center, and president of the Israel Radiological Association.

In addition, Pamela Wilcox, of Ridge, MD, will receive the Distinguished Achievement Award for notable service to the college and the profession. Wilcox served as ACR executive vice president of quality and safety, retiring in 2015 after 28 years of service.

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login